Some more info [GxP / QC / QA]

posted by Ohlbe – France, 2021-09-17 22:28 (1344 d 00:13 ago) – Posting: # 22587
Views: 11,234

Hi ElMaestro,

❝ One good question is what happens now. I would not be surprised if PanExcell and Synchron will cease to exist (might pop up under another name?), sponsors using the two CROs will be forced to abandon some/all of their MA's and/or repeat studies


Yes, indeed, in the USA: instructions to companies have now been posted on the FDA web site. Repeat all studies; therapeutic equivalence of already approved products is meanwhile changed to BX. Europe: it should not take them more than a year or two to decide what to do :sleeping:

❝ Have a look at the pdf files from FDA. Now answer this question: Which day were the letters issued?


❝ Do we really need to go looking for the date on the linking FDA page?


According to this new page: the letters were sent out on 15 September 2021.

Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,683 registered users;
62 visitors (0 registered, 62 guests [including 32 identified bots]).
Forum time: 22:41 CEST (Europe/Vienna)

Pharmacokinetics may be simply defined as
what the body does to the drug,
as opposed to pharmacodynamics, which may be defined as
what the drug does to the body.    Leslie Z. Benet

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5